The Value of Diagnostic Pre-Launch Planning for Targeted Therapies – Through the PD-L1 Lens - Diaceutics
+

The Value of Diagnostic Pre-Launch Planning for Targeted Therapies – Through the PD-L1 Lens



Peter Keeling
Sanna Jousi


Are you planning to launch a diagnostic alongside a targeted therapy in the next 18-24 months. This webinar highlights Diaceutics’ recent PD-L1 lost therapy opportunity assessment, which demonstrated that every $1 spent on smart diagnostic efficiency returns between $20-$40 in additional therapy revenues otherwise lost. It also highlights how effective diagnostic planning can maximize your therapy revenue opportunity.

Listen to this webinar to learn:

  • that $1 spent on smart diagnostic efficiency returns between $20-$40 in additional therapy revenues otherwise lost; and
  • why ineffective diagnostic launch planning can lead to lost therapy revenue and how, with the proper planning tools, the maximum therapy opportunity can be achieved.

Expert Insights

The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that...
EU IVD Regulation – What does it mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the...
View all expert insights

Competitive Benchmarking Reports

Pharma Precision Medicine Readiness Report 2019
PM Readiness Report 2018 Summary
View all reports

Publications

TRK fusion positive cancers: From first clinical data of a TRK inhibitor to future directions
Genetic alterations of neurotrophic tropomyosin or tyrosine receptor kinase (NTRK) 1/2/3 genes generate TRK fusion proteins have been reported in a variety of adult and child cancers from diverse cell/tissue lineages. Larotrectinib, a...
Challenges in the clinical implementation of precision medicine companion diagnostics
The pace of biomarker discovery has increased exponentially over the last few years,ushering in an era of precision medicine (PM) with a growing arsenal of treatments tailored to specific patient populations....
View all publications